A RANDOMIZED, OPEN-LABEL, PHASE 2 STUDY OF BORTEZOMIB AND DEXAMETHASONE WITH OR WITHOUT ELOTUZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

被引：0
|
作者：
Jakubowiak, A. [1 ]
Offidani, M. [2 ]
Pegourie, B. [3 ]
De La Rubia, J. [4 ]
Garderet, L. [5 ]
Laribi, K. [6 ]
Bosi, A. [7 ]
Marasca, R. [8 ]
Laubach, J. [9 ]
Mohrbacher, A. [10 ]
Carella, A. M. [11 ]
Singhal, A. K. [12 ]
Tsao, L. C. [12 ]
Lynch, M. [13 ]
Bleickardt, E. [13 ]
Jou, Y. M. [13 ]
Palumbo, A. [14 ]
机构：
[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[2] Osped Riuniti Ancona, Azienda Osped Univ, Ancona, Italy
[3] Hop Albert Michallon, CHU Grenoble, Grenoble, France
[4] HUP La Fe, Valencia, Spain
[5] Hop St Antoine, F-75571 Paris, France
[6] Ctr Hosp, Le Mans, France
[7] Azienda Osped Univ Careggi, Florence, Italy
[8] Azienda Osped Univ, Policlin Modena, Modena, Italy
[9] Dana Farber Canc Inst, Boston, MA 02115 USA
[10] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA
[11] IRCCS San Martino IST, Genoa, Italy
[12] AbbVie Biotherapeut Inc ABR, Redwood City, CA USA
[13] Bristol Myers Squibb Co, Wallingford, CT 06492 USA
[14] Osped Molinette, Azienda Osped Univ San Giovanni Battista Torino, Turin, Italy
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
S103
引用
收藏
页码：2 / 2
页数：1
相关论文
共 50 条
  • [41] Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: 2-Year Follow-up
    Palumbo, Antonio
    Offidani, Massimo
    Pegourie, Brigitte
    De La Rubia, Javier
    Garderet, Laurent
    Laribi, Kamel
    Bosi, Alberto
    Marasca, Roberto
    Laubach, Jacob P.
    Mohrbacher, Ann
    Carella, Angelo Michele
    Singhal, Anil K.
    Lynch, Mark
    Jou, Ying-Ming
    Jakubowiak, Andrzej
    BLOOD, 2015, 126 (23)
  • [42] Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Vs Ld in Patients with Newly Diagnosed Multiple Myeloma: Phase 2, Randomized, Open-Label Study in Japan
    Takezako, Naoki
    Ohta, Kensuke
    Handa, Hiroshi
    Hori, Mitsuo
    Kinoshita, Gen
    Shelat, Suresh
    Miyoshi, Masafumi
    Kubo, Kohmei
    BLOOD, 2017, 130
  • [43] ELOQUENT-2: A phase III, randomized, open-label trial of lenalidomide/dexamethasone (Len/Dex) with or without elotuzumab (Elo) in relapsed or refractory multiple myeloma (RR MM) (CA204-004).
    Lonial, Sagar
    Richardson, Paul Gerard Guy
    Moreau, Philippe
    Orlowski, Robert Z.
    San-Miguel, Jesus F.
    Dimopoulos, Meletios A.
    Palumbo, Antonio Pierangelo
    Facon, Thierry
    Vij, Ravi
    White, Darrell
    Reece, Donna Ellen
    Singhal, Anil
    Kroog, Glenn Scott
    Kopit, Justin
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Carfilzomib, Pomalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma Patients: A Multicenter, Open Label Phase 1/2 Study
    Bringhen, Sara
    Oliva, Stefania
    Liberati, Anna Marina
    Belotti, Angelo
    Larocca, Alessandra
    Bonello, Francesca
    Gaidano, Gianluca
    Bertazzoni, Paola
    Esma, Fabrizio
    Stocchi, Raffaella
    Malfitano, Alessandra
    Ribolla, Rossella
    Di Sano, Chiara
    Aschero, Simona
    Patriarca, Francesca
    De Paoli, Lorenzo
    Cafro, Anna Maria
    Sonneveld, Pieter
    Palumbo, Antonio
    Boccadoro, Mario
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E59 - E59
  • [45] Health Related Quality of Life Results from the Open-Label, Randomized, Phase III Endeavor Trial Evaluating Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma
    Ludwig, Heinz
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Mateos, Maria-Victoria
    Kaiser, Martin F.
    Feng, Shibao
    Cocks, Kim
    Buchanan, Jacqueline
    Weisel, Katja
    BLOOD, 2016, 128 (22)
  • [46] A phase II randomized study of bortezomib/dexamethasone (Bort/Dex) with or without elotuzumab (Elo) in patients (pts) with relapsed/refractory multiple myeloma (RR MM) (CA204-009).
    Jakubowiak, Andrzej J.
    White, Darrell
    Moreau, Philippe
    Facon, Thierry
    Vij, Ravi
    Kroog, Glenn Scott
    Kopit, Justin
    Singhal, Anil
    Palumbo, Antonio Pierangelo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [47] A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.
    Moreau, Philippe
    Richardson, Paul Gerard Guy
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc
    Facon, Thierry
    Vij, Ravi
    Reece, Donna Ellen
    White, Darrell
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn Scott
    Singhal, Anil
    Lonial, Sagar
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma-3-Year Safety and Efficacy Follow-up
    Dimopoulos, Meletios A.
    Lonial, Sagar
    White, Darrell
    Moreau, Philippe
    Palumbo, Antonio
    San Miguel, Jesus
    Shpilberg, Ofer
    Anderson, Kenneth C.
    Grosicki, Sebastian
    Spicka, Ivan
    Walter-Croneck, Adam
    Magen-Nativ, Hila
    Mateos, Maria-Victoria
    Belch, Andrew
    Reece, Donna
    Beksac, Meral
    Bleickhardt, Eric
    Poulart, Valerie
    Katz, Jessica
    Singhal, Anil K.
    Richardson, Paul G.
    BLOOD, 2015, 126 (23)
  • [49] Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study
    Ghobrial, Irene M.
    Weller, Edie
    Vij, Ravi
    Munshi, Nikhil C.
    Banwait, Ranjit
    Bagshaw, Meghan
    Schlossman, Robert
    Leduc, Renee
    Chuma, Stacey
    Kunsman, Janet
    Laubach, Jacob
    Jakubowiak, Andrzej J.
    Maiso, Patricia
    Roccaro, Aldo
    Armand, Philippe
    Dollard, Akari
    Warren, Diane
    Harris, Brianna
    Poon, Tiffany
    Sam, Amy
    Rodig, Scott
    Anderson, Kenneth C.
    Richardson, Paul G.
    LANCET ONCOLOGY, 2011, 12 (03): : 263 - 272
  • [50] Elotuzumab In Combination with Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study.
    Jakubowiak, Andrzej J.
    Benson, Don M., Jr.
    Bensinger, William
    Siegel, David S.
    Zimmerman, Todd M.
    Mohrbacher, Ann
    Richardson, Paul G.
    Afar, Daniel E. H.
    Singhal, Anil K.
    Anderson, Kenneth C.
    BLOOD, 2010, 116 (21) : 1245 - 1245
12345